• Artificial Intelligence for Rare Disease Diagnosis

  NCT07625436

  Not yet recruitingInterventionalNot ApplicableUpdated Jun 4, 2026
• Large Language Models Assist in Tumor MDT

  NCT07504367

  RecruitingInterventionalNot ApplicableUpdated Mar 31, 2026
• Ophthalmic Diseases and AI: an RCT Study

  NCT07154680

  CompletedObservationalUpdated Sep 4, 2025
• Improving AI-Assisted Medical Diagnosis and Triage by the General Public

  NCT07728513

  RecruitingInterventionalNot ApplicableUpdated Jul 27, 2026
• AI Models in Clinical Pathology Diagnosis: A Multicenter RCT

  NCT07408167

  Not yet recruitingInterventionalNot ApplicableUpdated Feb 13, 2026
• Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study

  NCT07378358

  RecruitingObservationalUpdated Jan 30, 2026

ClinicalTrials.gov ID

NCT07650799

Lead Sponsor

Peking Union Medical College HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

1,056Estimated

Last Update Posted

Jul 31, 2026Actual

Start Date

Aug 1, 2026Estimated

Primary Completion Date

Jul 1, 2027Estimated

Completion Date

Dec 1, 2027Estimated

Official Title

A Multicentre Randomised Controlled Trial of LLM-Assisted Diagnostic Support in Patients With Suspected Rare or Diagnostically Unresolved Disease

Brief Summary

A multicentre randomised controlled trial evaluating whether a rare-disease diagnostic large language model can improve diagnostic quality, efficiency, and health-economic outcomes for physicians managing patients with suspected rare or diagnostically unresolved disease.

Detailed Description

Rare disease patients commonly experience prolonged diagnostic odysseys rooted in limited rare disease recognition, phenotypic heterogeneity, and dispersed diagnostic clues. Diagnostic decision-support large language models may improve first-visit consultations by integrating prior records, generating structured analyses, and proposing candidate diagnoses, thereby shortening diagnostic pathways and improving appropriate genetic testing referral.

Participating physicians will provide care under both AI-assisted and standard diagnostic workflows. Eligible patients will be individually randomised to receive either AI-assisted diagnostic support or standard clinical practice.

In the intervention arm, physicians will have diagnostic support from AI when seeing patients. In the control arm, patients are seen under standard hospital workflow without any generative AI tools. Outcomes adjudicated by an independent Expert Committee blinded to arm assignment; adjudicators access no AI-generated materials.

A prospective within-trial economic evaluation will be conducted alongside the randomized trial. Healthcare resource use and costs associated with the diagnostic pathway will be collected.

• Rare Disorders
• Rare Diseases

• AI system

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Patient Inclusion Criteria:

• Any age. Legal guardian co-signs consent for minors or individuals lacking legal capacity.
• Diagnostically unresolved or suspected rare disease, with at least one prior complete clinical evaluation at a secondary-level or higher institution yielding no confirmed explanatory diagnosis.
• First presentation to the enrolling institution for the current condition, with no prior records in the institutional HIS or outpatient system.
• No prior genetic testing related to the current condition; no results or reports available.
• Written informed consent provided voluntarily by patient or legal guardian, with commitment and ability to complete structured follow-up.

Patient Exclusion Criteria:

• Confirmed diagnosis (clinical, pathological, or molecular) explaining the primary symptoms.
• Emergency presentation, critical illness, or any condition incompatible with trial participation.
• Neither patient nor legally authorised proxy able to complete follow-up.
• Concurrent enrollment in another interventional study with diagnostic accuracy or genetic testing yield as a primary endpoint.
• Prior use of another AI system has already yielded a confirmed diagnosis for the current condition.

Physician Inclusion Criteria

• Licensed physician in internal medicine, neurology, pediatrics, general medicine, rare disease, or a related specialty.
• ≥2 years of clinical practice; competent to manage rare disease patients; stratified into junior or senior tier.
• Voluntary participation with written informed consent.

Physician Exclusion Criteria

• No longer in clinical practice, or unable to fulfill required outpatient duties during the study period.
• Unwilling to provide informed consent or to permit protocol-required collection of consultation and questionnaire data.
• Currently enrolled in another AI-assisted clinical workflow, or expected to be unable to comply with the procedures.

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

Peking Union Medical College HospitalOTHER

Collaborators

Cangzhou Central HospitalOTHER

Zhangzhou Municipal HospitalOTHER

Dongguan People's HospitalOTHER_GOV

First People's Hospital of FoshanOTHER

Guizhou Provincial People's HospitalOTHER

Tianjin Children's HospitalOTHER

The First People's Hospital of YunnanOTHER

Qinghai People's HospitalOTHER

czszxyyirb@163.com+86-0317-2075013

ts407yy@sina.com+86-0938-8229999